Annual CEO industry survey to check the 'pulse' of the Australian industry


Tuesday, 28 January, 2014

AusBiotech calls on industry leaders (CEOs and MDs) to respond to the annual Biotechnology Industry Position Survey 2014 in order to contribute to the annual snapshot and build the advocacy platform for the year to come. 

The survey, once again supported by Grant Thornton, is in the process of being posted and emailed to biotechnology company leaders and responses are invited by 24 February 2014.

AusBiotech conducts the confidential survey early each year to formally seek opinions and information from the leaders of the industry it represents, thus getting a comprehensive view of the Australian biotechnology sector based on industry experience, knowledge, key metrics and political insight.

While input on public policy is a year-round, ongoing and core part of AusBiotech’s work, the survey informs efforts, and the industry’s contribution and support make those efforts far more powerful. The results help build metrics about the significance of the industry and its perspectives and help AusBiotech to make strong statements about the magnitude of issues, trends and company practices.

The collated results appear in a printed report that is widely used as a source of industry views and information, as well as giving valuable ballast to AusBiotech’s advocacy efforts.

This year AusBiotech and Grant Thornton will be conducting three facilitated focus groups (NSW, Vic and Qld) for CEOs, MDs or their C-suite delegate, in April, to discuss the ‘Government Policy’ section of the survey in more detail.

If you have any questions about the survey or the focus groups and your company’s participation, please contact Lorraine Chiroiu (AusBiotech’s Communications Manager) at lchiroiu@ausbiotech.org or 03 9828 1400.

Related News

Cancer drug eliminates bone metastasis in lab models

Researchers have developed a novel treatment that is specific to breast cancer bone metastasis...

TGA rejects Alzheimer's drug due to safety concerns

The TGA determined that the demonstrated efficacy of lecanemab in treating Alzheimer's did...

Defective sperm doubles pre-eclampsia risk in IVF patients

A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd